Pfizer. The name itself holds a weight, a history etched into the very fabric of modern medicine. And now, it finds itself in a curious position. A period of transition, a shedding of old growth. The loss of patent exclusivity is not a death, but a dormancy. A necessary retreat before the next flowering. It is as if the company, having reached a certain height, is allowing some branches to fall, preparing for a new, perhaps more resilient, form.
They unloaded it all, you see. Gone. Zero shares held by quarter’s end. A clean break. $3.13 million moved around like so much dust in the wind. It’s all just numbers, really. Numbers dancing for a little while, then fading.
The so-called “Magnificent Seven” stocks, for example, are currently valued as if they hold the patents to gravity itself. At a combined price-to-earnings ratio hovering around 28, they seem to be betting heavily on humanity’s continued ability to ignore basic economic principles. As the late, great Warren Buffett (a man who clearly understood the universe’s inherent unfairness) observed, popularity and sensible investment rarely coincide. The truly productive positions, as a general rule, are the ones everyone else has forgotten about, or, preferably, never even considered. (This is largely because the universe is a profoundly illogical place, and things only become valuable when someone decides they are. It’s a system fraught with peril, frankly.)
In a video posted on January 22nd from Colorado, Hoskinson described his visit as a way to reconnect with what he considers the most important part of Cardano. He also explained it’s a starting point for the next step in Cardano’s development: improving the competitiveness of top applications by integrating Cardano with the features of Midnight.
Let’s look at which one might not lose quite so much money, eventually. Investing in quantum computing is a bit like betting on the first manned mission to Alpha Centauri. It could happen. It’s just…unlikely to make you rich before you’re dust.
Lamb Weston, for the uninitiated, isn’t some quaint family farm. It’s a global behemoth in the frozen potato industry. Think of it: a company dedicated entirely to turning perfectly good potatoes into various shapes and sizes, then freezing them for your convenience. It’s a remarkable feat of engineering, really. And a testament to our collective desire for instant gratification. They supply restaurants, grocery stores, and anyone else who feels the urge for a quick fry. Revenue for the trailing twelve months clocked in at $6.47 billion, a figure that, when you think about it, represents an awful lot of potatoes. Net income was a respectable $392.30 million, which, presumably, doesn’t all go towards potato-themed bonuses.
Real estate, particularly, felt the pinch. It’s a creature of the rate, sensitive to every shift in the wind. And the pandemic… well, that was a blow. Empty storefronts, shuttered theaters, a world holding its breath. It felt, for a time, like the end of an era.
The filing with the SEC – a document as cold and clinical as a coroner’s report – reveals this accumulation occurred during the final quarter. It isn’t merely the acquisition, however, but the weight of it. This stake now constitutes a disturbing 18.3% of Kawa’s reportable U.S. equity assets. A fifth of their fortune, entrusted to the cold, calculating logic of brick, mortar, and the precarious future of scientific endeavor. It speaks, does it not, to a profound lack of faith in… everything else?
UBS Group AG, the world’s preeminent purveyor of financial prudence, is reportedly on the brink of permitting its private banking clientele to engage in the speculative frenzy of cryptocurrency trading. According to whispers from those in the know (who, of course, prefer to remain anonymous, lest they be accused of spreading such nonsense), the bank has been locked in months of tortured deliberation over how best to structure this offering. The plans, we are told, remain under review, and no final decision has been taken-a mercy, one might think, for all concerned.
Last year was, shall we say, generous to Robinhood. Revenue doubled, profits soared, funded accounts swelled. A veritable cornucopia of capital! They’ve even dabbled in event contracts and tokenization – embracing the future, they claim. As a shareholder, I concede, they’re pulling the right levers. But let’s be frank: the price has become…ambitious. Forty-two times forward earnings? One begins to suspect the market is valuing hope, not fundamentals. A rather precarious foundation, wouldn’t you agree?